66th ASH Annual Meeting: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies

Symposia: Emerging Tools, Techniques, and Artificial Intelligence in Hematology Oral and Poster Abstracts
Oral

Research, Fundamental Science, Artificial intelligence (AI), Adult, Acute Myeloid Malignancies, AML, MDS, Translational Research, Lymphomas, MPN, Elderly, Health outcomes research, Clinical Research, B Cell lymphoma, Bioinformatics, Genomics, Chronic Myeloid Malignancies, Pediatric, Diseases, Neonatal, Immune Disorders, Real-world evidence, Computational biology, Lymphoid Malignancies, Adverse Events, Young adult , Emerging technologies, Survivorship, Myeloid Malignancies, Biological Processes, Microbiome, Technology and Procedures, Gene editing, Human, Study Population, Multi-systemic interactions, Imaging, Machine learning, Molecular testing, Omics technologies, Pathology

Room 30 (San Diego Convention Center)

Moderators:

Niroshan Nadarajah, MSc, MLL Munich Leukemia Laboratory and Daniel Royston, DPhil, FRCPath, MBBChir,

Disclosures:

Royston: Ground Truth Labs Ltd.: Consultancy; Johnson & Johnson: Consultancy.

9:30 AM

103

Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia

Francisco Marchi, BS¹, Ann-Kathrin Schade²^*, Vivek M. Shastri, PhD¹, Xueyuan Cao, PhD³^*, Raul C. Ribeiro, MD⁴, Jeffrey E. Rubnitz, MD, PhD⁵, Jeffery M Klco, MD, PhD⁶, Alan S Gamis, MD, MPH⁷, Rhonda E. Ries, MA⁸^*, Anders Kolb, MD⁹, Richard Aplenc¹⁰, Todd A. Alonzo, PhD¹¹^*, Stanley Pounds, PhD¹²^*, Soheil Meshinchi, MD, PhD⁸ and Jatinder K. Lamba, PhD¹

¹Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL
²University of Florida, Gainesville, FL
³University of Tennessee Health Science Center, Memphis, TN
⁴Division of Leukemia/Lymphoma, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
⁵Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
⁶Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
⁷Hematology/Oncology/BMT, Children's Mercy Kansas City, Kansas City, MO
⁸Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA
⁹Leukemia Lymphoma Society, Wilmington, DE
¹⁰Children's Hospital of Philadelphia, Philadelphia, PA
¹¹Univ. of Southern California Keck School of Med., Monrovia, CA
¹²Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN

9:45 AM

104

Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome

Alessia Campagna, MD¹^*, Frederick Clasen²^*, Theo Portlock, PhD³^*, Matteo Zampini, PhD⁴^*, Francesca Ficara, PhD^5,6^*, Laura Crisafulli, PhD^1,5^*, Matteo Brindisi^5,7^*, Giuseppe Martano^8,9^*, Elena Saba, PhD¹⁰^*, Marta Ubezio, MD⁶^*, Antonio Russo, MD¹^*, Gabriele Todisco, MD¹¹^*, Giulia Maggioni, MD⁶^*, Luca Lanino, MD¹, Alessandro Buizza¹²^*, Nicole Pinocchio, MSc⁴^*, Denise Ventura, MSc⁴^*, Filippo Viviani, MD⁶^*, Elena Torre, MD¹³^*, Rita Antunes Dos Reis¹⁴^*, Ettore Rocchi¹⁵^*, Gastone Castellani, PhD¹⁶^*, Mathias Uhlen, PhD³^*, Claire Harrison¹⁷, Shahram Kordasti, MD, PhD¹³, Matteo Giovanni Della Porta, MD¹^* and Saeed Shoaie, PhD²^*

¹IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy
²King's College London, London, United Kingdom
³Science for Life Laboratory, Royal Institute of Technology (KTH), Stockholm, Sweden
⁴Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy
⁵Institute for Genetic and Biomedical Research, Milan Unit, CNR, Milan, Italy
⁶IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
⁷Humanitas Clinical and Research Center, IRCCS, Rozzano, AL, Italy
⁸IRCCS Humanitas Research Hospital, Rozzano (MI), Italy
⁹Institute of Neuroscience, National Research Council of Italy (CNR), Milano, Italy
¹⁰Humanitas Clinical and Research Center, IRCCS, Rozzano, Milano, Italy
¹¹Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
¹²IRCCS Humanitas Research Hospital, Rozzano, Italy
¹³Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
¹⁴Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
¹⁵Department of Medical and Surgical Sciences, Bologna University, Bologna, Italy
¹⁶Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
¹⁷Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

10:00 AM

105

Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)

Elisabetta Sauta, PhD¹^*, Flavio Sartori, MSc²^*, Luca Lanino, MD³, Gianluca Asti, MSc¹^*, Saverio D'Amico, MSc^1,4^*, Mattia Delleani¹^*, Elena Riva, PhD³^*, Matteo Zampini, PhD³^*, Elena Zazzetti, MSc¹^*, Marilena Bicchieri, PhD¹^*, Giulia Maggioni, MD¹^*, Alessia Campagna, MD¹^*, Gabriele Todisco, MD^5,6^*, Cristina Astrid Tentori, MD¹^*, Marta Ubezio, MD¹^*, Antonio Russo, MD¹^*, Alessandro Buizza⁷^*, Francesca Ficara, PhD^1,8^*, Laura Crisafulli, PhD^3,8^*, Matteo Brindisi^3,8^*, Denise Ventura, MSc³^*, Nicole Pinocchio, MSc³^*, Daoud Rahal, MD¹^*, Cesare Lancellotti, MD⁹^*, Arturo Bonometti, MD^1,6^*, Luca Di Tommaso, MD^1,6^*, Victor Savevski, MEng¹^*, Armando Santoro, MD⁷^*, Nicolas Riccardo Derus, PhD¹⁰^*, Daniele Dall'Olio, PhD¹¹^*, Valeria Santini, MD¹², Francesc Sole, PhD¹³, Uwe Platzbecker, MD¹⁴, Pierre Fenaux, MD¹⁵, Maria Diez-Campelo, MD, PhD¹⁶^*, Rami S. Komrokji, MD¹⁷, Guillermo Garcia-Manero, MD¹⁸, Torsten Haferlach, MD¹⁹, Shahram Kordasti, MD, PhD^20,21, Amer M. Zeidan, MD²², Gastone Castellani, PhD²³^*, Tiziana Sanavia, PhD²^*, Piero Fariselli, PhD²^* and Matteo Giovanni Della Porta, MD^1,6^*

¹IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
²Computational Biomedicine Unit, Department of Medical Sciences, University of Torino, Turin, Italy
³IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy
⁴Train s.r.l., Milan, Italy
⁵IRCCS Humanitas Research Hospital, Houston, TX
⁶Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy
⁷IRCCS Humanitas Research Hospital, Rozzano, Italy
⁸Institute for Genetic and Biomedical Research, Milan Unit, CNR, Milan, Italy
⁹Struttura Complessa di Anatomia Patologica, Policlinico di Modena, Modena, Italy
¹⁰Department of Physics and Astronomy (DIFA), University of Bologna, Bologna, Italy
¹¹IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
¹²AOU Careggi, University of Florence, Firenze, Italy
¹³Myelodysplastic Syndromes Research Group, Institut De Recerca Josep Carreras, Badalona, Barcelona, Spain
¹⁴Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
¹⁵Hôpital Saint-Louis, Université de Paris 7, Paris, France
¹⁶Hospital Clínico Universitario de Salamanca, Salamanca, Spain
¹⁷Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
¹⁸MD Anderson Cancer Center, Houston, TX
¹⁹MLL Munich Leukemia Laboratory, Munich, Germany
²⁰Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
²¹Hematology Unit, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
²²Yale School of Medicine, Smilow Cancer Hospital at Yale New Haven, New Haven, CT
²³Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

10:15 AM

106

Machine Learning Based Prediction of One Year Mortality after Allogeneic Hematopoietic Cell Transplantation (alloHCT) Highlights Importance of Pre-Transplant Immunocompetence

Thomas Meyer, MD¹^*, Robert Meyer, PhD²^*, Daniela Oelke, PhD³^*, Ralph Wäsch¹, Justus Duyster, MD¹^*, Jürgen Finke, MD¹, Robert Zeiser, MD¹ and Claudia Wehr, MD¹^*

¹Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
²alcemy GmbH, Berlin, Germany
³Offenburg University of Applied Sciences, Offenburg, Germany

10:30 AM

107

Analysis of Avapritinib Clinical Trial Data Generates a Highly Accurate Predictive Model for Advanced Systemic Mastocytosis Versus Indolent Systemic Mastocytosis Based on Peripheral Blood Testing

Ben Lampson, MD, PhD¹^*, Aaron Zakharyan, PhD¹^*, Virginia O. Volpe, MD², Shai Shimony, MD², Hongliang Shi³^* and Daniel Deangelo, MD, PhD²^*

¹Blueprint Medicines Corporation, Cambridge, MA
²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³Blueprint Medicines Corporation, Boston, MA

10:45 AM

108

Deep Learning Predicts Risk of Large B-Cell Lymphoma Progression upon R-CHOP Therapy from Baseline Histology

Samaneh Abbasi Sureshjani¹^*, Anil Yüce¹^*, Christian Doerig¹^*, Agata Mosinska¹^*, Patrick Kimes, PhD²^*, Murali Kesavan³^*, Connie Lee Batlevi², Yanwen Jiang²^* and Markus D Herrmann¹^*

¹F. Hoffmann-La Roche AG, Basel, Switzerland
²Genentech, Inc., South San Francisco, CA
³F. Hoffmann-La Roche Ltd, London, United Kingdom

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

803.O2.3 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies